Comprehensive research on past and future therapeutic Strategies devoted to treatment of amyotrophic lateral sclerosis

Basit Öğe Kaydı
dc.contributor.authorSever, Belgin
dc.contributor.authorÇiftçi, Halil İbrahim
dc.contributor.authorDemirci,Hasan
dc.contributor.authorSever, Hilal
dc.contributor.authorOcak, Firdevs
dc.contributor.authorYuluğ, Burak
dc.contributor.authorTateishi, Hiroshi
dc.contributor.authorTateishi, Takahisa
dc.contributor.authorOtsuka, Masami
dc.contributor.authorFujita, Mikako
dc.contributor.authorBaşak, Ayşe Nazlı
dc.date.accessioned2022-09-12T10:32:30Z
dc.date.available2022-09-12T10:32:30Z
dc.date.issued2022
dc.departmentALKÜ, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractAmyotrophic lateral sclerosis (ALS) is a rapidly debilitating fatal neurodegenerative disorder, causing muscle atrophy and weakness, which leads to paralysis and eventual death. ALS has a multifaceted nature affected by many pathological mechanisms, including oxidative stress (also via protein aggregation), mitochondrial dysfunction, glutamate-induced excitotoxicity, apoptosis, neuroinflammation, axonal degeneration, skeletal muscle deterioration and viruses. This complexity is a major obstacle in defeating ALS. At present, riluzole and edaravone are the only drugs that have passed clinical trials for the treatment of ALS, notwithstanding that they showed modest benefits in a limited population of ALS. A dextromethorphan hydrobromide and quinidine sulfate combination was also approved to treat pseudobulbar affect (PBA) in the course of ALS. Globally, there is a struggle to prevent or alleviate the symptoms of this neurodegenerative disease, including implementation of antisense oligonucleotides (ASOs), induced pluripotent stem cells (iPSCs), CRISPR-9/Cas technique, non-invasive brain stimulation (NIBS) or ALS-on-a-chip technology. Additionally, researchers have synthesized and screened new compounds to be effective in ALS beyond the drug repurposing strategy. Despite all these efforts, ALS treatment is largely limited to palliative care, and there is a strong need for new therapeutics to be developed. This review focuses on and discusses which therapeutic strategies have been followed so far and what can be done in the future for the treatment of ALS.
dc.identifier.doi10.3390/ijms23052400
dc.identifier.endpage30en_US
dc.identifier.issue5en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12868/1565
dc.identifier.urihttps://www.mdpi.com/1422-0067/23/5/2400
dc.identifier.volume23en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAmyotrophic lateral sclerosis (ALS)
dc.subjectOxidative stress
dc.subjectProtein aggregation
dc.subjectGlutamate excitotoxicity
dc.subjectApoptosis
dc.subjectNeuroinflammation
dc.subjectAxonal degeneration
dc.subjectEdaravone
dc.subjectRiluzole
dc.subjectInduced pluripotent stem cells (iPSCs)
dc.titleComprehensive research on past and future therapeutic Strategies devoted to treatment of amyotrophic lateral sclerosis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.pdf
Boyut:
3.21 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin / Full text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu